Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on developing precision medicines for immune-mediated diseases and cancer. The company’s core activity centers on targeting signal regulatory proteins (SIRP) to selectively deplete disease-driving myeloid and T cells while preserving normal immune function. Its approach replaces broad immunosuppression with targeted immune cell depletion, aiming to transform treatment paradigms in areas such as…
Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on developing precision medicines for immune-mediated diseases and cancer. The company’s core activity centers on targeting signal regulatory proteins (SIRP) to selectively deplete disease-driving myeloid and T cells while preserving normal immune function. Its approach replaces broad immunosuppression with targeted immune cell depletion, aiming to transform treatment paradigms in areas such as secondary hemophagocytic lymphohistiocytosis (sHLH) and T/NK cell malignancies.
Electra Therapeutics generates revenue through the development and potential commercialization of its product candidates, primarily ipsoprubart and ELA822, which are designed for specific disease indications. Revenue is anticipated from future sales of these biologics upon regulatory approval, with initial focus on sHLH and expansion into hematologic malignancies and chronic immune-inflammatory diseases. The company serves patients treated by hematologist-oncologists and specialists in immunology and oncology, particularly those with severe hyperinflammatory syndromes and relapsed/refractory T/NK cell malignancies.
Electra Therapeutics operates through the following segments: Ipsoprubart for sHLH and hematologic malignancies, and ELA822 for chronic T cell-mediated immune and inflammatory diseases.
- Ipsoprubart for sHLH and hematologic malignancies: This segment focuses on the development of ipsoprubart, a novel pan-SIRP monoclonal antibody engineered with an enhanced-effector Fc domain to deplete pathogenic myeloid and T cells. Ipsoprubart is being advanced in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), including the SURPASS Phase 2/3 trial and the COMPASS natural history study as an external control. The segment also explores ipsoprubart’s activity in relapsed/refractory T/NK cell malignancies, where it has shown a 100% objective tumor response rate in exploratory analyses, with ongoing Phase 1 clinical trials expected to yield initial data in the second half of 2027.
- ELA822 for chronic T cell-mediated immune and inflammatory diseases: This segment advances ELA822, a SIRP g -specific monoclonal antibody designed to selectively deplete activated pathogenic T cells while sparing naïve and regulatory immune populations. ELA822 is being evaluated for chronic T cell-mediated diseases such as giant cell arteritis (GCA) and graft-versus-host disease (GvHD), supported by nonclinical data showing selective T cell depletion and in vivo activity in humanized models. The company initiated a Phase 1 trial in healthy volunteers in Europe in August 2026, with data expected in the first half of 2027, followed by a Phase 1/2 trial in patients with T cell-mediated immune disorders anticipated in mid-2027, subject to regulatory approval.
Electra Therapeutics occupies a pioneering position in the biopharmaceutical industry as the first company to advance SIRP-targeted precision immune cell depletion into clinical development with proof-of-concept in humans. Its differentiated approach preserves the CD47-SIRP a immune surveillance pathway while leveraging activation-dependent SIRP expression to eliminate pathogenic cells, setting it apart from competitors focused on CD47 blockade. The company benefits from a proprietary library of SIRP-targeted antibodies, deep expertise in SIRP biology, and a leadership team with a proven track record in commercializing first-in-class therapies across immunology, hematology, and oncology.
Electra Therapeutics serves patients diagnosed with secondary hemophagocytic lymphohistiocytosis (sHLH), particularly those with malignancy-associated HLH (mHLH), as well as individuals with relapsed/refractory T/NK cell malignancies and chronic T cell-mediated immune disorders such as giant cell arteritis and graft-versus-host disease. The company’s customer base includes hematologist-oncologists, immunologists, and specialty treaters at academic medical centers and community hospitals managing these complex conditions.